Title: AMFine Title

URL Source: https://docs.oppl.io/etf/IE000JKS50V3_18-02-2026.pdf

Published Time: Fri, 19 Jun 2026 12:49:13 GMT

Number of Pages: 2

Markdown Content:
Amundi S&P World Health Care Screened UCITS ETF Dist 

# Key Investor Information 

This document provides you with key investor information about this Sub-Fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this Sub-Fund. You are advised to read it so you can make an informed decision about whether to invest. 

# Amundi S&P World Health Care Screened UCITS ETF Dist A Sub-Fund of AMUNDI ETF ICAV 

# ISIN codes: (A) , (D) IE000JKS50V3 

This ICAV has appointed Amundi Ireland Limited, an entity part of Amundi group, as its Management Company 

# Objectives and Investment Policy 

This Sub-Fund is passively managed. The Sub-Fund is a financial product that promotes among other characteristics ESG characteristics pursuant to Article 8 of the Disclosure Regulation. The objective of this Sub-Fund is to track the performance of S&P World Health Care Weighted & Screened Index (the "Index"), and to minimize the tracking error between the net asset value of the Sub-Fund and the performance of the Index. The anticipated level of the tracking error, under normal market conditions, is indicated in the prospectus of the Sub-Fund. The Index is a net total return index, meaning that dividends net of tax paid by the index constituents are included in the Index return The Sub-Fund promotes environmental and/or social characteristics through among others, replicating an Index integrating an environmental, social and governance ("ESG") rating. The Index is an equity index that measures the performance of eligible equity securities from the S&P World Information Technology Index (the "Parent Index"). The Parent Index is designed to measure the performance of large and mid-cap information technology companies in developed markets excluding Korea which make up approximately 85% of the total available capital. Information technology companies are identified by reference to the GICS. The information technology sector comprises companies that offer software and information technology services, manufacturers and distributors of technology hardware and equipment such as communications equipment, cellular phones, computers, electronic equipment, and semiconductors. The Index is selected and weighted to enhance ESG profiles, and reduce carbon emission intensity, all compared to the Parent Index. The Index applies several ESG filters (e.g. exclusions filters to exclude companies involved in controversial business activities (e.g. controversial weapon), or involved in ESG controversies) and optimization constraints (GHG intensity reduction and identical S&P Global ESG Score or improvement of such score compared to the Parent Index). The exposure to the Index will be achieved through a direct replication, mainly by making direct investments in transferable securities and/or other eligible assets representing the Index constituents in a proportion extremely close to their proportion in the Index. The Investment Manager will be able to use derivatives in order to deal with inflows and outflows and which relate to the Index or constituents of the Index for investment and/or efficient portfolio management. In order to generate additional income to offset its costs, the Sub-Fund may also enter into securities lending operations. Information on how the Index is consistent with environmental, social and governance characteristics is available in the prospectus. More information about the composition of the Index and its operating rules are available in the prospectus and at: spdji.com The Index value is available via Bloomberg (SPDSEHUN). The Sub-Fund integrates sustainability risks as outlined in more detail in section "Sustainable Investment" of the prospectus. Dividend Policy : the accumulation share automatically retains, and re-invests, net investment incomes within the Sub-Fund when the distribution share pays dividends annually. The minimum recommended holding term is 5 years. The Sub-Fund's shares are listed and traded on one or more stock exchanges. In normal circumstances, you may deal in shares during the trading hours of the stock exchanges, provided that the Market Makers can maintain market liquidity. Only authorised participants (e.g. selected financial institutions) may deal in shares directly with the Sub-Fund on the primary market. Further details are provided in the prospectus of the ICAV. 

# Risk and Reward Profile   

> Lower risk, Higher risk,
> Typically lower reward Typically higher reward

# 1 2 3 4 5 6 7

The risk level of this Sub-Fund mainly reflects the market risk arising from investments in equities of the industry sector the Sub-Fund invests in. Historical data may not be a reliable indication for the future. Risk category shown is not guaranteed and may shift over time. The lowest category does not mean 'risk free'. Your initial investment does not benefit from any guarantee or protection. Important risks materially relevant to the Sub-Fund which are not adequately captured by the indicator: 

Liquidity risk: in case of low trading volume on financial markets, any buy or sell trade on these markets may lead to important market variations/fluctuations that may impact your portfolio valuation. 

Counterparty risk: represents the risk of default of a market participant to fulfil its contractual obligations vis-à-vis your portfolio. 

Operational risk: this is the risk of default or error within the different service providers involved in managing and valuing your portfolio. 

Currency risk : You are exposed to the currency exchange risk between the currencies of the stocks in the Index and the currency of the share in which you are invested. The occurrence of any of these risks may have an impact on the net asset value of your portfolio. 

1Amundi S&P World Health Care Screened UCITS ETF Dist 

# Charges 

The charges you pay are used to pay the costs of running the Sub-Fund, including the costs of marketing and distributing it. These charges reduce the potential growth of your investment. 

One-off charges taken before or after you invest 

Entry charge* 3.00% 

Exit charge* 3.00% 

Conversion charge Not applicable This is the maximum that might be taken out of your money before the proceeds of your investment are paid out. Charges taken from the Sub-Fund over a year 

Ongoing charges %Charges taken from the Sub-Fund under certain specific conditions 

Performance fee None 

The entry, exit and conversion charges shown are maximum figures applied on the primary market only. In some cases you might pay less - you can find this out from your financial adviser. 

The ongoing charges figure is based on expenses for the current year. This figure may vary from year to year. It excludes: Performance fees Portfolio transaction costs, except in the case of an entry/exit charge paid by the Sub-Fund when buying or selling units in another collective investment undertaking. The ongoing charges displayed are estimated. For each accounting period, the Sub-Fund's annual report will display the exact amount. * Entry and exit charges will only apply when shares are subscribed or redeemed directly from the Sub-Fund, and will not apply when investors buy or sell such shares on stock exchanges. Investors dealing on exchange will pay fees charged by their intermediaries. Such charges can be obtained from intermediaries. For more information about charges, please see charges paragraph of the prospectus of the UCITS, which is available at: amundi.ie 

# Past Performance      

> 002.1% 7.8% 0.3% 002.1% 7.8% 0.2% 2021 2022 2023 2024 2025 % . 012345678Amundi S&P World Health Care Screened UCITS ETF Dist Benchmark

The chart has a limited value as a guide to future performance. The annualised performances displayed in this diagram are calculated net income reinvested and net of all charges taken by the Sub-Fund. Sub-Fund launch: 2022. Share class launch: 2025. The reference currency is the Euro. The reference Index is : S&P World Health Care Weighted & Screened Index 

# Practical Information 

Name of the depositary: HSBC Continental Europe . 

Further information about the ICAV (prospectus, periodical reports) can be obtained in English, free of charge, at the following address: Amundi Ireland Limited, 1 George's Quay Plaza, Georges Quay, Dublin 2, Ireland. 

The details of the up-to-date remuneration policy, including, but not limited to, a description of how remuneration and benefits are calculated, the identity of persons responsible for awarding the remuneration and benefits are available by means of the following website: https://www.amundi.ie and a paper copy will be made available free of charge upon request. 

Other practical information (e.g. latest net asset value, transparency policy and information about the asset composition of the Sub-Fund) can be obtained on the internet site amundi.ie or amundietf.com. 

Indicative net asset value is published by the relevant stock exchanges. 

The ICAV contains a large number of other Sub-Funds and other classes which are described in the prospectus. Conversion into shares of another Sub-Fund of the ICAV may be made, subject to the conditions of the prospectus. 

Each Sub-Fund corresponds to a distinct part of the assets and liabilities of the ICAV. As a consequence, the assets of each Sub-Fund are exclusively available to satisfy the rights of investors in relation to that Sub-Fund and the right of creditors whose claims have arisen in connection with the creation, the operation or the liquidation of that Sub-Fund. 

This document describes a Sub-Fund of the ICAV. The prospectus and periodical reports are prepared for the entire ICAV named at the beginning of this document. 

The ICAV is subject to Irish taxation legislation which may have an adverse impact on the personal tax of the investor. 

Amundi Ireland Limited may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the prospectus for the ICAV. 

> *********************

This ICAV is authorised in Ireland and regulated by the Central Bank of Ireland. Amundi Ireland Limited is authorised and regulated by the Central Bank of Ireland. This key investor information is accurate as at February 18, 2026. 

2